

IN THE CLAIMS:

Please cancel claims 2, 3, 13, 14, 18, 20, and 25-46, and 48-70 without prejudice.

D1 sub 16. (Amended) A method for clearing extra-corporeal blood or blood products from IL-6 or IL-6
E6 receptor molecules using a peptide, peptide composition or antibody of claim 1.

D2 19. (Amended) A method for exerting agonistic IL-6 activity at concentrations that are relatively
equivalent to 7.5 to 120 $\mu\text{g/ml}$ using a peptide according to claim 7.

D3 sub 23. (Amended) A method for manufacturing a medicament comprising a peptide, or peptide
E7 combination for topical or intra-mammary application according to claim 1.

D4 47. (Amended) A method for manufacturing a pharmaceutical preparation according to claim 7 for
topical or intra-mammary application.

Please add the following new claims:

sub 71. The peptide of claim 5 having at least one string of 5 consecutive amino acids long in
E8 common with the following amino acid sequence: EWGPRSTPSLTTKAVLLLVRKFQNSPAED
(SEQ ID NO: 11).

D5 72. The peptide composition of claim 9 wherein at least four peptides are linked with
sub 33 branching oligolysines.

73. The peptide composition of claim 10 wherein at least four peptides are linked with
branching oligolysines.